Adecatumumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAdecatumumab
Drug Alias NameMonoclonal antibody MT201阿迪妥木单抗阿德木单抗Human anti-EpCAM monoclonal antibody MT201adecatumumabum +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsEpithelial cell adhesion molecule inhibitors
TargetsEpithelial cell adhesion molecule
Therapy Area/IndicationsLiver NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyFrance
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmgen Research (Munich) Gmbh
Active IndicationsN/A
Inactive IndicationsLiver NeoplasmsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia